Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$0.66
$0.05(4.46%)
At close: 4:00 PM EDT
$0.66
$0.05(4.46%)
Day’s Range― - ―
52-Week Range$0.50 - $2.44
Previous Close$1.17
Volume9.77K
Average Volume (3M)430.74K
Market Cap
$21.09M
Enterprise Value$65.14M
Total Cash (Recent Filing)$6.53M
Total Debt (Recent Filing)$171.00K
Price to Earnings (P/E)―
Beta-0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,119,820
10 Day Avg. Volume61,185
30 Day Avg. Volume430,741
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap3.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.71K
Enterprise Value/Ebitda-8.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesThe substantial reduction in annual losses indicates improving cost control and a less severe operating deficit than in earlier years. Although Beyondspring remains unprofitable, continued loss reduction could preserve capital longer and improve its ability to direct resources toward clinical development.
Capital-efficient China CollaborationShifting China trial funding to Biolin reduces Beyondspring’s direct cash requirements while preserving access to potentially valuable clinical data for global development. The structure can improve capital efficiency and support the broader registration strategy without requiring wholly owned China operations.
Regulatory Development SupportFDA Fast Track designation provides a formal regulatory pathway intended to facilitate development and review of the targeted plinabulin combination. It does not assure approval, but it may support regulatory interaction and help advance the program toward a meaningful clinical decision point.
Bears Say
Pre-commercial Revenue ProfileThe absence of meaningful revenue leaves Beyondspring dependent on clinical and regulatory outcomes rather than an established commercial franchise. Without recurring product sales, the company has limited operating leverage and earnings visibility, making future financial performance highly dependent on development progress.
Negative Equity And Shrinking AssetsNegative shareholder equity and a materially smaller asset base indicate weak balance-sheet resilience despite modest stated debt. This reduces financial flexibility, leaves less internal capacity to absorb setbacks, and can make future financing more important as clinical and regulatory spending continues.
Persistent Cash BurnContinued negative operating and free cash flow means the business is not yet self-funding its development program. Ongoing cash consumption increases reliance on external financing or available liquidity, potentially constraining trial execution and reducing flexibility in capital allocation.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.50 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $21.09M.
When is Beyondspring Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beyondspring Inc’s earnings last quarter?
Currently, no data Available
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Ownership Overview
10.96% Insiders
2.19% Mutual Funds
9.31% Other Institutional Investors
75.60% Public Companies and
Individual Investors